Likewise, disrupting the balance between α-secretase and non-α-secretase pathways leads to increased BACE1 activity, resulting in Aβ oligomers and plaque accumulation, making BACE1 activity a critical therapeutic target in the AD treatment. The gene discussed is BACE1; the disease is Alzheimer disease.